Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity

[1]  C. Caldas,et al.  Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). , 2010, The Lancet. Oncology.

[2]  S. Gunn.  The vanguard has arrived in the clinical laboratory: array-based karyotyping for prognostic markers in chronic lymphocytic leukemia. , 2010, The Journal of molecular diagnostics : JMD.

[3]  T. O'Leary.  Past and Present as Prologue , 2010 .

[4]  P. Diest,et al.  Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification , 2010, Breast Cancer Research and Treatment.

[5]  S. Gunn,et al.  Validation of an Array CGH Test for HER2 Status Using Tumor-Targeted DNA Extraction from Formalin Fixed Tissue: Comparison with Fresh Frozen Tissue Results. , 2009 .

[6]  A. Ashworth,et al.  Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis , 2009, The Journal of pathology.

[7]  G. Viale.  Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer , 2009, The Journal of pathology.

[8]  S. Gunn,et al.  Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event , 2009, Modern Pathology.

[9]  C. Chang,et al.  The rewards and challenges of array-based karyotyping for clinical oncology applications , 2009, Leukemia.

[10]  J. Silverman,et al.  Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma , 2009, Modern Pathology.

[11]  Sampsa Hautaniemi,et al.  The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome , 2009, International journal of cancer.

[12]  E. Perez,et al.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. , 2009, The Lancet. Oncology.

[13]  Alan Mackay,et al.  Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.

[14]  R. Tuma.  Inconsistency of HER2 test raises questions. , 2007, Journal of the National Cancer Institute.

[15]  M. Dowsett,et al.  Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.

[16]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[17]  M. Press.  How is Her-2/neu status established when Her-2/neu and chromosome 17 centromere are both amplified? , 2006, American journal of clinical pathology.

[18]  R. West,et al.  Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. , 2006, American journal of clinical pathology.

[19]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[20]  J. Bartlett,et al.  Chromosome 17 Aneusomy is Associated with Poor Prognostic Factors in Invasive Breast Carcinoma , 2004, Breast Cancer Research and Treatment.